This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Shine, N. Articles by Düzgünes, N. Search for Related Content PubMed PubMed Citation Articles by Shine, N. Articles by Düzgünes, N. Social Bookmarking                         What's this?

Concise Review: The Anti-HIV-1 Activity Associated with Saliva

Department of Microbiology, University of the Pacific, School of Dentistry, 2155 Webster Street, San Francisco, California 94115-2399

Krystyna Konopka

Department of Microbiology, University of the Pacific, School of Dentistry, 2155 Webster Street, San Francisco, California 94115-2399

Nejat Düzgüne

Department of Microbiology, University of the Pacific, School of Dentistry, 2155 Webster Street, San Francisco, California 94115-2399, Department of Biopharmaceutical Sciences, School of Pharmacy, University of California, San Francisco, California 94143

This review summarizes the data on the anti-human immunodeficiency virus (HIV) activity associated with saliva and the possible routes of oral transmission of HIV. Saliva can be passed from an HIV-infected individual to an uninfected person via sexual or non-sexual activities. The relative risk of HIV transmission through saliva is a subject of continuing concern for dental practitioners. HIV-infected individuals frequently have oral lesions that can cause bleeding and release of the virus into the oral cavity. In addition, viral p24 and HIV-1 RNA were detected in tonsils and adenoids even in asymptomatic seropositive individuals. Nevertheless, the potential HIV-infectivity of saliva is low, although both infectious HIV-1 and HIV DNA have been detected in saliva. This observation has led to the suggestion that saliva may contain factors that inhibit HIV-1 infectivity. At least two anti-HIV activities have been partially characterized: (i) physical entrapment of HIV by high-molecular-weight molecules (e.g., mucins), and (ii) inhibition of viral infection by soluble proteins. Several studies have indicated that, of the salivary proteins evaluated, recombinant secretory leukocyte protease inhibitor (rSLPI) could inhibit HIV-1 infection in macrophages at physiological concentrations. The anti-HIV activity of the serine protease inhibitor rSLPI is most likely due to its interaction with a cell-surface molecule(s) other than the primary HIV-1 receptor, CD4, and may involve (i) inhibition of cell-surface serine protease(s), and/or (ii) interaction with other human-specific co-factors essential for viral entry.

Key Words: HIV, saliva • mucins • SLPI.

Journal of Dental Research, Vol. 76, No. 2, 634-640 (1997)
DOI: 10.1177/00220345970760020301


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. H. Kazmi, J. R. Naglik, S. P. Sweet, R. W. Evans, S. O'Shea, J. E. Banatvala, and S. J. Challacombe Comparison of Human Immunodeficiency Virus Type 1-Specific Inhibitory Activities in Saliva and Other Human Mucosal Fluids Clin. Vaccine Immunol., October 1, 2006; 13(10): 1111 - 1118. [Abstract] [Full Text] [PDF]

				E. A. Acheampong, Z. Parveen, L. W. Muthoga, V. Wasmuth-Peroud, M. Kalayeh, A. Bashir, R. Diecidue, M. Mukhtar, and R. J. Pomerantz Molecular Interactions of Human Immunodeficiency Virus Type 1 with Primary Human Oral Keratinocytes J. Virol., July 1, 2005; 79(13): 8440 - 8453. [Abstract] [Full Text] [PDF]

				X. Wang, X. Li, L. Xu, Y. Zhan, S. Yaish-Ohad, J. A. Erhardt, F. C. Barone, and G. Z. Feuerstein Up-Regulation of Secretory Leukocyte Protease Inhibitor (SLPI) in the Brain after Ischemic Stroke: Adenoviral Expression of SLPI Protects Brain from Ischemic Injury Mol. Pharmacol., October 1, 2003; 64(4): 833 - 840. [Abstract] [Full Text] [PDF]

				X. Liu, J. Zha, H. Chen, J. Nishitani, P. Camargo, S. W. Cole, and J. A. Zack Human Immunodeficiency Virus Type 1 Infection and Replication in Normal Human Oral Keratinocytes J. Virol., March 15, 2003; 77(6): 3470 - 3476. [Abstract] [Full Text] [PDF]

				J. A. Bosch, E. J. C. de Geus, T. J. M. Ligtenberg, K. Nazmi, E. C. I. Veerman, J. Hoogstraten, and A. V. N. Amerongen Salivary MUC5B-Mediated Adherence (Ex Vivo) of Helicobacter pylori During Acute Stress Psychosom Med, January 1, 2000; 62(1): 40 - 49. [Abstract] [Full Text] [PDF]

				K. Konopka, N. Shine, E. Pretzer, and N. Duzgunes Secretory Leukocyte Protease Inhibitor (SLPI): Oxidation of SLPI Does Not Explain Its Variable Anti-HIV Activity Journal of Dental Research, December 1, 1999; 78(12): 1773 - 1776. [Abstract] [PDF]

				S. Kennedy, C. Davis, W.R. Abrams, P.C. Billings, T. Nagashunmugam, H. Friedman, and D. Malamudl Submandibular Salivary Proteases: Lack of a Role in Anti-HIV Activity Journal of Dental Research, July 1, 1998; 77(7): 1515 - 1519. [Abstract] [PDF]